Spero Therapeutics (NASDAQ:SPRO) reported its Q4 earnings results on Wednesday, March 13, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
Earnings
Spero Therapeutics beat estimated earnings by 1060.0%, reporting an EPS of $0.96 versus an estimate of $-0.1.
Revenue was up $26.08 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.03 which was followed by a 2.0% drop in the share price the next day.
Here's a look at Spero Therapeutics's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.03 | -0.34 | -0.33 | 0.04 |
| EPS Actual | -0.06 | -0.23 | -0.25 | 0.55 |
| Revenue Estimate | 14.97M | 1.07M | 1.00M | 22.87M |
| Revenue Actual | 25.47M | 2.72M | 2.07M | 47.44M |
To track all earnings releases for Spero Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.